NCT04097028 - Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2019

Primary Completion Date

December 16, 2022

Study Completion Date

February 5, 2025

Conditions

Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

Interventions

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

DRUG

Oxaliplatin

Given IV

Trial Locations (2)

14203

Roswell Park Cancer Institute, Buffalo

73104

Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Science Center, Oklahoma City

All Listed Sponsors

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Roswell Park Cancer Institute

OTHER